Optimization of a Subcutaneous Epithelioid Hemangioendothelioma Xenograft Model for Evaluation of Preclinical Therapeutics
Epithelioid hemangioendothelioma (EHE) is an ultra-rare vascular sarcoma characterized by an unpredictable clinical trajectory and lack of established standard-of-care treatment regimens. Despite the pressing need for effective therapeutic strategies, the scarcity of clinically relevant preclinical models remains a major barrier to drug development. To address this challenge, we used a…
Epithelioid hemangioendothelioma (EHE) is an extremely rare vascular tumor with unpredictable progression and no established treatments. The lack of suitable preclinical models hinders drug development. Researchers used a patient-derived EHE cell line to create and validate a subcutaneous xenograft model in mice. They found that high cell densities led to adverse systemic effects and unsuitable tumour growth for drug screening.
Conversely, low cell densities resulted in stable, reproducible xenografts following traditional growth patterns. Histological examination confirmed the tumours' EHE characteristics, such as ERG and CAMTA1 expression. Treatment sensitivity to mTOR inhibition was observed, mirroring the original patient sample. Using the optimized CDX model, researchers could monitor tumour growth and potential anti-tumour effects over extended periods. This platform offers a practical method for assessing and comparing potential EHE therapies.
Written by urgent.news from bioRxiv's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
